Merck Phase 2b/3 Trial for Remigromig Meets Primary Endpoint
By Chris Wack
Merck said it saw positive topline results for its Phase 2b/3 trial for remigromig in adults with diabetic macular edema.
The pharmaceutical company said the trial, the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig met its primary endpoint.
Remigromig is an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site pathway, which is involved in the repair and maintenance of the blood-retinal-barrier.
The company said that at 52 weeks, two different doses of remigromig independently demonstrated non-inferiority for mean change from baseline in best-corrected visual acuity in patients with DME.
Both doses of remigromig were generally well tolerated. Higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations due to adverse events were observed. Further analyses are under way to characterize these findings.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 24, 2026 07:27 ET (11:27 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States